Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock

BOSTON—Tammi L. Gaskins, the Chief Commercial Officer of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), has recently sold shares of the company. According to a filing with the Securities and Exchange Commission, Gaskins disposed of 2,563 shares of Class A Common Stock on May 16, 2025, at a price of $0.58 per share. This transaction amounted to a total value of $1,486. The sale comes as the stock has experienced significant pressure, down over 90% in the past year, according to InvestingPro data. The company’s market capitalization currently stands at approximately $108 million.

Following this sale, Gaskins holds 242,596 shares in the company. The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. This transaction was not a discretionary trade but occurred automatically to satisfy these obligations. InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 3.34, suggesting adequate resources to meet short-term obligations. Subscribers to InvestingPro can access 11 additional key insights about IRWD, including detailed valuation metrics and growth forecasts.

In other recent news, Ironwood Pharmaceuticals is facing significant challenges following the FDA’s requirement for an additional Phase 3 trial of its drug candidate, apraglutide. This development has led to a series of downgrades by analysts, impacting the company’s financial outlook. Craig-Hallum downgraded Ironwood from Buy to Hold and reduced the price target to $1.00, citing increased risks due to the delayed approval of apraglutide and concerns over debt and the upcoming loss of exclusivity for its key product, Linzess. Wells Fargo (NYSE:WFC) also downgraded Ironwood to Equal Weight, pointing out the financial strain of the new trial requirement. Similarly, Jefferies downgraded the stock to Hold with a price target of $0.70, expressing concerns over the FDA’s focus on lower than expected exposure levels of apraglutide in clinical trials. Leerink Partners maintained a Market Perform rating but reduced its price target to $1.00, highlighting the financial uncertainties surrounding the additional trial. Ironwood’s CEO, Tom McCourt, remains optimistic about apraglutide’s potential, despite the setbacks. The company is exploring strategic alternatives, including a potential sale of Linzess-related cash flows, to navigate these challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.